Shireen Vali

2.6k citations

67 papers · 2.1k indexed · h-index 23

Co-authors: Taher Abbasi Shweta Kapoor Gautam Sethi Muthu K. Shanmugam Alan Prem Kumar Peramaiyan Rajendran Kwang Seok Ahn M. M. Srinivas Bharath
Topics: Cancer Genomics and Diagnostics (12 papers)Protein Degradation and Inhibitors (12 papers)Multiple Myeloma Research and Treatments (10 papers)
Cited by: Toxicology Molecular Medicine Complementary and alternative medicine
Journals: Journal of Biological Chemistry Journal of Clinical Oncology Blood
Partner nations: United States Singapore India

In The Last Decade

Shireen Vali

64 papers receiving 2.1k citations

Peers

Countries citing papers authored by Shireen Vali

Since Specialization

Citations

This map shows the geographic impact of Shireen Vali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shireen Vali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shireen Vali more than expected).

Fields of papers citing papers by Shireen Vali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shireen Vali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shireen Vali. The network helps show where Shireen Vali may publish in the future.

Co-authorship network of co-authors of Shireen Vali

This figure shows the co-authorship network connecting the top 25 collaborators of Shireen Vali. A scholar is included among the top collaborators of Shireen Vali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shireen Vali. Shireen Vali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC 2024 ·JTO Clinical and Research Reports ·Jacqueline V. Aredo,Heather A. Wakelee,Kavitha Ramchandran,Joel W. Neal,Maximilian Diehn,Angela B. Hui,Ameen A. Salahudeen,Bernice Y. Kwong,Gerald J. Berry,H. Henry Guo,Kristen Cunanan,Shireen Vali,(unknown),Vivian W. L. Tsang,(unknown),Matthew J. Loza,Brittany Johnson,(unknown),Sukhmani K. Padda	1
2	Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers 2021 ·Cell Death Discovery ·Ser Yue Loo,Nicholas Syn,(unknown),(unknown),Amudha Deivasigamani,Tuan Zea Tan,Aye Aye Thike,Shireen Vali,Shweta Kapoor,Xiaoyuan Wang,Jiong‐Wei Wang,Puay Hoon Tan,George W. Yip,Gautam Sethi,Ruby Yun‐Ju Huang,Kam M. Hui,Lingzhi Wang,Boon Cher Goh,Alan Prem Kumar	12
3	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis 2019 ·Leukemia Research ·Brett M. Stevens,Amanda Winters,Jonathan A. Gutman,Aaron Fullerton,(unknown),(unknown),(unknown),Qi Wei,Taher Abbasi,Shireen Vali,(unknown),Leylah Drusbosky,Christopher R. Cogle,Andrew Hammes,Diana Abbott,Craig T. Jordan,Clayton A. Smith,Daniel A. Pollyea	4
4	iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). 2018 ·Journal of Clinical Oncology ·Leylah Drusbosky,Kimberly E. Hawkins,(unknown),Glenda G. Anderson,Shireen Vali,Taher Abbasi,Fei Zou,Nosha Farhadfar,Hemant S. Murthy,Biljana Horn,Helen Leather,Paul Castillo,Randy A. Brown,Maxim Norkin,John W. Hiemenz,John R. Wingard,Jack W. Hsu,Christopher R. Cogle	0
5	Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC—a computational study 2017 ·Oral Surgery Oral Medicine Oral Pathology and Oral Radiology ·Amber M. Bates,(unknown),Qian Fang,Taher Abbasi,Shireen Vali,Kim A. Brogden	8
6	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models 2016 ·Cancer Immunology Immunotherapy ·(unknown),(unknown),Amber M. Bates,(unknown),(unknown),Carol L. Fischer,Deepak Parashar,Janet M. Guthmiller,Georgia K. Johnson,Taher Abbasi,Shireen Vali,Kim A. Brogden	17
7	PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression 2016 ·Translational Cancer Research ·Kim A. Brogden,Shireen Vali,Taher Abbasi	7
8	Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs 2014 ·Journal of Translational Medicine ·Pengfei Jiang,(unknown),Ying S. Chao,Ila Sri Bharati,Valentina Fogal,Sandra Pastorino,Xiuli Cong,Natsuko Nomura,(unknown),Taher Abbasi,Shireen Vali,Sandeep C. Pingle,Milan Makale,Santosh Kesari	92
9	Oral inflammation, a role for antimicrobial peptide modulation of cytokine and chemokine responses 2013 ·Expert Review of Anti-infective Therapy ·Kim A. Brogden,Georgia K. Johnson,Steven D. Vincent,Taher Abbasi,Shireen Vali	20
10	Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus 2013 ·Scientific Reports ·(unknown),Karl G. Kohlgraf,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Ann Progulske‐Fox,Joseph E. Cavanaugh,Shireen Vali,Kim A. Brogden	22
11	Isorhamnetin Inhibits Proliferation and Invasion and Induces Apoptosis through the Modulation of Peroxisome Proliferator-activated Receptor γ Activation Pathway in Gastric Cancer 2012 ·Journal of Biological Chemistry ·Lalitha Ramachandran,Kanjoormana Aryan Manu,Muthu K. Shanmugam,Li Feng,Kodappully Sivaraman Siveen,Shireen Vali,Shweta Kapoor,Taher Abbasi,(unknown),Duane T. Smoot,Hassan Ashktorab,Patrick Tan,Kwang Seok Ahn,Chun Wei Yap,Alan Prem Kumar,Gautam Sethi	126
12	Honokiol inhibits signal transducer and activator of transcription‐3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP‐1 2011 ·Journal of Cellular Physiology ·Peramaiyan Rajendran,Feng Li,Muthu K. Shanmugam,Shireen Vali,Taher Abbasi,Shweta Kapoor,Kwang Seok Ahn,Alan Prem Kumar,Gautam Sethi	136
13	Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice 2011 ·Journal of Molecular Medicine ·Muthu K. Shanmugam,Peramaiyan Rajendran,Feng Li,(unknown),Shireen Vali,Taher Abbasi,Shweta Kapoor,Ashish K. Sharma,Alan Prem Kumar,Paul C. Ho,Kam M. Hui,Gautam Sethi	122
14	Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma 2010 ·Molecular Cancer Therapeutics ·Diana Cirstea,Teru Hideshima,Scott J. Rodig,Loredana Santo,Samantha Pozzi,Sonia Vallet,Hiroshi Ikeda,Giulia Perrone,Güllü Görgün,Kishan Patel,Neil Desai,Peter Sportelli,Shweta Kapoor,Shireen Vali,Siddhartha Mukherjee,Nikhil C. Munshi,Kenneth C. Anderson,Noopur Raje	136
15	A Computer Simulation of Progesterone and Cox2 Inhibitor Treatment for Preterm Labor 2010 ·PLoS ONE ·Ozlem Equils,(unknown),Calvin J. Hobel,Roger Smith,Charles F. Simmons,Shireen Vali	15
16	Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line 2009 ·Cancer Chemotherapy and Pharmacology ·Karnati R. Roy,Gorla V. Reddy,(unknown),Smita Agarwal,(unknown),Shireen Vali,Pallu Reddanna	52
17	Insights into the effects of α-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data 2008 ·Free Radical Biology and Medicine ·Shireen Vali,Shankar J. Chinta,Jie Peng,(unknown),Narendra Kumar Singh,Praveen Sharma,(unknown),Julie K. Andersen,M. M. Srinivas Bharath	14
18	C-Phycocyanin inhibits 2-acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and In silico analysis 2007 ·Archives of Biochemistry and Biophysics ·Karnati R. Roy,Kalle M. Arunasree,(unknown),Aparna Rachamallu,Gorla V. Reddy,Shireen Vali,Pallu Reddanna	23
19	Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies 2007 ·Free Radical Biology and Medicine ·(unknown),Rajeswara Babu Mythri,Shireen Vali,M. M. Srinivas Bharath	129
20	Role of the sarcoplasmic reticulum in regulating the activity-dependent expression of the glycogen phosphorylase gene in contractile skeletal muscle cells 2000 ·Journal of Cellular Physiology ·Shireen Vali,Richard C. Carlsen,Isaac N. Pessah,Fredric A. Gorin	11

About Shireen Vali

Shireen Vali is a scholar working on Hematology, Toxicology and Cancer Research, having authored 67 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (12 papers), Protein Degradation and Inhibitors (12 papers) and Multiple Myeloma Research and Treatments (10 papers). The work is most often cited by research in Toxicology (198 citations), Molecular Medicine (136 citations) and Complementary and alternative medicine (174 citations). Shireen Vali has collaborated with scholars based in United States, Singapore and India. Frequent co-authors include Taher Abbasi, Shweta Kapoor, Gautam Sethi, Muthu K. Shanmugam, Alan Prem Kumar, Peramaiyan Rajendran, Kwang Seok Ahn, M. M. Srinivas Bharath, Rajeswara Babu Mythri and Ansu Kumar. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact